Metraipolis › archive › dc_95d7cc71ac51
Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response — Europe PMC PMID:36465486
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/36465486
- DOI
- 10.1080/2162402x.2022.2152248
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-10T04:05:51.808Z
- SHA-256 of the archived text
714fecd180c936ebb7de595fadc090738830413cc54ad90267b18a6c36b64829- Stable URL of this page
https://metraipolis.com/documento/dc_95d7cc71ac51
How to cite
Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response — Europe PMC PMID:36465486 — Europe PMC (en), https://europepmc.org/article/MED/36465486 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_95d7cc71ac51 (Metraipolis archive dc_95d7cc71ac51, sha256 714fecd180c936ebb7de595fadc090738830413cc54ad90267b18a6c36b64829)
BibTeX
@misc{dc95d7cc71ac51,
title = {Selective depletion of polymorphonuclear myeloid derived suppressor cells in tumor beds with near infrared photoimmunotherapy enhances host immune response — Europe PMC PMID:36465486},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/36465486},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_95d7cc71ac51; sha256 714fecd180c936ebb7de595fadc090738830413cc54ad90267b18a6c36b64829},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36465486. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
The immune system is recognized as an important factor in regulating the development, progression, and metastasis of cancer. Myeloid-derived suppressor cells (MDSCs) are a major immune-suppressive cell type by interfering with T cell activation, promoting effector T cell apoptosis, and inducing regulatory T cell expansion. Consequently, reducing or eliminating MDSCs has become a goal of some systemic immunotherapies. However, by systemically reducing MDSCs, unwanted side effects can occur. Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed treatment that selectively kills targeted cells without damaging adjacent normal cells. The aim of this study is to evaluate the antitumor efficacy of MDSC-directed NIR-PIT utilizing anti-Ly6G antibodies to specifically destroy polymorphonuclear (PMN)-MDSCs in the tumor microenvironment (TME) in syngeneic mouse models. PMN-MDSCs were selectively eliminated within tumors by Ly6G-targeted NIR-PIT. There was significant tumor growth suppression and prolonged survival in three treated tumor models. In the early phase after NIR-PIT, dendritic cell maturation/activation and CD8 + T cell activation were enhanced in both intratumoral tissues and tumor-draining lymph nodes, and NK cells demonstrated increased expression of cytotoxic molecules. Host immunity remained activated in the TME for at least one week after NIR-PIT. Abscopal effects in bilateral tumor models were observed. Furthermore, the combination of NIR-PIT targeting cancer cells and PMN-MDSCs yielded synergistic effects and demonstrated highly activated host tumor immunity. In conclusion, we demonstrated that selective local PMN-MDSCs depletion by NIR-PIT could be a promising new cancer immunotherapy. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: Oncoimmunology, 2022 (prima pubblicazione 2022-11-30). Identificativi: PMID 36465486 · PMCID PMC9718564 · DOI 10.1080/2162402x.2022.2152248. Parole chiave degli autori: Cancer; Cancer therapy; Ly6g; Myeloid-derived Suppressor Cell (Mdsc); Near-infrared Photoimmunotherapy (Nir-pit). Descrittori MeSH principali: Myeloid-Derived Suppressor Cells. Pagina: https://europepmc.org/article/MED/36465486 — https://doi.org/10.1080/2162402x.2022.2152248. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-10T03:35:36.723Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.